Please assess the completion status of the following clinical trial:

Trial Title: Oral Galactose in Children With Steroid Resistant Nephrotic Syndrome

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. 2-21 years old~2. Biopsy proven FSGS or minimal change with steroid resistance~3. Presence of FSPF (defined as permeability activity \>0.5)~4. Presence of nephrotic range proteinuria (urine protein: creatinine ratio \>2) at the time of enrollment.~5. Persistent nephrotic range proteinuria despite being on stable immunosuppressive medications (cyclosporine, tacrolimus or mycophenolate mofetil) for at least 12 weeks and/or persistent nephrotic range proteinuria despite being on stable dose of angiotensin converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs) for 12 weeks.~6. Stable serum creatinine (change of less than 0.3 mg/dl) in the prior 3 months.~7. Schwartz estimated (e) glomerular filtration rate (GFR) \>60ml/min/1.73m2~Exclusion Criteria:~1. Secondary FSGS~2. Onset of nephrotic syndrome in infancy.~3. Presence of acute renal failure (as defined by acute kidney injury criteria) at the time of enrollment. These children can be enrolled 1 month after resolution of acute renal failure (ARF).~4. Decreasing renal function (persistent increase in serum creatinine of greater than 0.3 mg/dl over baseline in the prior 3 months).~5. Use of another investigational drug~6. Pregnant or unable to comply with contraceptive measures in females of child bearing age~7. eGFR \< 60 ml/min per 1.73 m2~8. Children with Galactosemia~9. Children with type 1 or 2 diabetes

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: 21 Years
- Healthy Volunteers: f

Study Arms:
- Galactose (Type: EXPERIMENTAL): Oral galactose will be given at a dose of 0.2gm/kg/dose twice a day (BID) to a maximum of 15 gm BID for a period of 16 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).